ClinicalTrials.gg
RecruitingNCT03943316Updated Sep 18, 2026

Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer

An observational study in Ovarian Cancer, sponsored by New Mexico Cancer Research Alliance. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by New Mexico Cancer Research Alliance · Observational

From the registry’s dates

  • Started Dec 2015; still recruiting 10 years 11 months later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
Female
01

Study summary

Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.

Read the detailed description

The purpose of this study is to collect ascites fluid obtained from ovarian cancer patients during cytoreductive surgery or paracentesis at the University of New Mexico Hospital or Cancer Center. Cancer cells and immune cells from the ascites fluid will be used to test novel immunotherapies for ovarian cancer treatment and to establish patient derived xenograft models to perform preclinical testing on a cancer cell population that better models the heterogeneity in patient disease

02

Conditions studied

  • Ovarian Cancer

Keywords

  • Ovarian Cancer
  • Ascites
03

In context

Ovarian Neoplasms

3,381 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

This study's planned enrollment of 500 is above the median of 200 across 616 observational studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

New Mexico Cancer Research Alliance is the lead sponsor of 72 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

All female participants, regardless of ethnicity, who are undergoing cytoreductive surgery for ovarian cancer are eligible for this study; All participants will be eighteen years old or older; Patients must be suspected of having a pathological diagnosis or clinical suspicion of ovarian cancer and be scheduled for surgery for tumor resection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All female participants, regardless of ethnicity, who are undergoing cytoreductive surgery for ovarian cancer are eligible for this study
  • All participants will be eighteen years old or older
  • Patients must be suspected of having a pathological diagnosis or clinical suspicion of ovarian cancer and be scheduled for surgery for tumor resection.
  • Ability to understand and the willingness to sign a written document.
  • Pathologic confirmation of a diagnosis of epithelial adenocarcinoma of the ovary, fallopian tube, or primary peritoneal cancer (serous, mucinous, clear cell, endometrioid, undifferentiated, mixed, transitional cell)
  • Women of must have a negative qualitative serum pregnancy test ≤ 2 weeks prior to study entry.
  • A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

Exclusion criteria

Exclusion Criteria:

  • We do not intend to include participants if they are unable to provide for this study themselves (e.g. mentally ill patients who require health care proxies to consent for any medical intervention), or vulnerable populations such as prisoners.
  • Minors under age eighteen.
  • Pregnant women.
  • Final pathologic diagnosis that does not confirm invasive epithelial ovarian, tubal, or primary peritoneal cancer
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Collect ascites fluid obtained from ovarian cancer patients during cytoreductive surgery or paracentesis

    To elucidate the conditions of the tumor environment that contribute to cancer dissemination in the peritoneal cavity through ex vivo evaluation of malignant ascites collected from women with ovarian, tubal, or primary peritoneal cancer.

    Time frame: 5 years

Secondary outcomes

  1. To correlate specific features of peritoneal cell populations or soluble factors with patient outcome.

    To correlate specific features of peritoneal cell populations or soluble factors with patient outcome.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87131, United States
    Recruiting
    • Amy Overby · ContactAoverby1@salud.unm.edu · 505-272-5557
    • Sharareh Sazesh, MS · Contactssazesh@salud.unm.edu
    • Sarah Adams, MD · Principal investigator
    • Carolyn Muller, MD · Sub investigator
    • Bridget Wilson, PhD · Sub investigator
    • Laurie Hudson, PhD · Sub investigator
    • Angela Wandinger-Ness, PhD · Sub investigator
    • Helen Hathaway, PhD · Sub investigator
    • Eric Prossnitz, PhD · Sub investigator
    • Mara Steinkamp, PhD · Sub investigator
    • Sabrina Samudio-Ruiz, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03943316
Lead sponsor
New Mexico Cancer Research Alliance
Responsible party
Sponsor
First posted
May 9, 2019
Start date
Dec 2, 2015
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Sep 18, 2026

Study contacts

Sarah Adams, MD
Contact
SAdams@salud.unm.edu
(505) 925-0461
Amy Overby
Contact
Aoverby1@salud.unm.edu
505-272-5557
Sarah Adams, MD
principal investigator · UNM Comprehensive Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion